## MDT: Medtronic plc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.4% below STRENGTH zone (3.0-6.0%); PEG 3.79 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($94.93)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Shorepoint Capital Partners LLC Purchases Shares of 35,714 Medtronic PLC $MDT**
- Source: MarketBeat | 20251216T122440 | Bullish | Relevance: 100%
- Shorepoint Capital Partners LLC initiated a new position in Medtronic PLC (NYSE:MDT) during the third quarter, acquiring 35,714 shares valued at approximately $3.40 million. Medtronic recently beat quarterly estimates, announced a quarterly dividend of $0.71, and multiple analysts have raised their price targets on the stock, contributing to a "Moderate Buy" consensus rating.

**2. Westwood Holdings Group Inc. Has $11.70 Million Stake in Medtronic PLC $MDT**
- Source: MarketBeat | 20251215T135327 | Bullish | Relevance: 100%
- Westwood Holdings Group Inc. increased its stake in Medtronic PLC (NYSE:MDT) by 8.4% in the second quarter, bringing its total holdings to $11.70 million. Other institutional investors like Vanguard Group Inc., Geode Capital Management LLC, and Bank of New York Mellon Corp also boosted their positions in the medical technology company. Medtronic's stock is trading up, with a market cap of $128.02 billion, and recently announced a quarterly dividend of $0.71 per share.

**3. Reynders McVeigh Capital Management LLC Reduces Position in Medtronic PLC $MDT**
- Source: MarketBeat | 20251215T130240 | Somewhat-Bullish | Relevance: 100%
- Reynders McVeigh Capital Management LLC significantly reduced its stake in Medtronic PLC by 95.4% in the second quarter, selling 195,951 shares and retaining 9,501 shares valued at $828,000. Despite this, Medtronic reported strong Q2 earnings, exceeding analyst expectations, and received a consensus "Moderate Buy" rating with an average target price of $110.44 from analysts. The company also declared a quarterly dividend of $0.71 per share.

**4. MASTERINVEST Kapitalanlage GmbH Acquires Shares of 14,942 Medtronic PLC $MDT**
- Source: MarketBeat | 20251215T120815 | Bullish | Relevance: 100%
- MASTERINVEST Kapitalanlage GmbH recently purchased 14,942 shares of Medtronic PLC (NYSE:MDT) valued at approximately $1,302,000 during the second quarter. This acquisition is part of broader institutional investment in Medtronic, with many other firms also adjusting their positions in the medical technology company. Medtronic has also announced a quarterly dividend of $0.71 per share, reflecting a 2.8% annualized yield.

**5. National Bank of Canada FI Reduces Stock Position in Medtronic PLC $MDT**
- Source: MarketBeat | 20251215T102439 | Bullish | Relevance: 100%
- National Bank of Canada FI has reduced its stock holdings in Medtronic PLC (NYSE:MDT) by 6.4% in the second quarter, selling 82,931 shares and retaining 1,220,745 shares valued at approximately $106.4 million. Despite this reduction, other major institutional investors like Norges Bank and Vanguard Group Inc. have significant positions, with institutional investors collectively owning 82.06% of the company's stock. Medtronic reported stronger-than-expected quarterly earnings and revenue, and analysts maintain a broadly positive outlook with an average target price of $110.44.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 8, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |
| 2025-11-19 | RBC Capital | $118 | $111 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |
| 2025-11-19 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.38M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Valuation stretched: PEG 3.8x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 8 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.79 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (8 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $126.4B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.79 |
| Forward P/E | 16.1 |
| Current P/E | 17.4 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.8% to -0.4% (+3.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.4pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.08x) but short-term weakness (below SMA20). MACD histogram bearish (-0.66), momentum weakening. RSI neutral at 46. OFD pattern: -MUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.44% (CS: 23) | Neutral |
| RSI_14 | 46.3 | Neutral |
| MACD Histogram | -0.66 | Bearish |
| vs SMA20 | 0.972x | Below |
| vs SMA50 | 1.015x | Above |
| vs SMA200 | 1.082x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $98.57
- **Stop Loss:** $94.93 (3.7% risk)
- **Target:** $102.21 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 329
- **Position Value:** $32,429.53
- **Portfolio %:** 32.43%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*